Abstract
Background Cholesterol efflux capacity (CEC) predicts cardiovascular disease (CVD) independently of HDL cholesterol (HDL-C) levels. Isolated small HDL particles are potent promoters of macrophage CEC by the ABCA1 pathway, but the underlying mechanisms are unclear.
Methods We used model system studies of reconstituted HDL and plasma from control and lecithin-cholesterol acyltransferase (LCAT)-deficient subjects to investigate the relationships among the sizes of HDL particles, the structure of APOA1 in the different particles, and the CECs of plasma and isolated HDLs.
Results We quantified macrophage and ABCA1 CEC of four distinct sizes of reconstituted HDL (r-HDL). CEC increased as particle size decreased. MS/MS analysis of chemically crosslinked peptides and molecular dynamics simulations of APOA1 (HDL’s major protein) indicated that the mobility of that protein’s C-terminus was markedly higher and flipped off the surface in the smallest particles. To explore the physiological relevance of the model system studies, we isolated HDL from LCAT-deficient subjects, whose small HDLs–like r-HDLs–are discoidal and composed of APOA1, cholesterol, and phospholipid. Despite their very low plasma levels of HDL particles, these subjects had normal CEC. In both the LCAT-deficient subjects and control subjects, the CEC of isolated extra-small HDL (a mixture of extra-small and small HDL by calibrated ion mobility analysis) was 3–5-fold greater than that of the larger sizes of isolated HDL. Incubating LCAT-deficient plasma and control plasma with human LCAT converted extra-small and small HDL particles into larger particles, and it markedly inhibited CEC.
Conclusions We present a mechanism for the enhanced CEC of small HDLs. In smaller particles, the C-termini of the two antiparallel molecules of APOA1 are flipped off the lipid surface of HDL. This extended conformation allows them to engage with ABCA1. In contrast, the C-termini of larger HDLs are unable to interact productively with ABCA1 because they form a helical bundle that strongly adheres to the lipid on the particle. Enhanced CEC, as seen with the smaller particles, predicts decreased CVD risk. Thus, extra-small and small HDLs may be key mediators and indicators of HDL’s cardioprotective effects.
Clinical Perspective
Using chemical crosslinking and molecular dynamics simulations, we showed that the C-termini of APOA1, HDL’s major protein, have increased mobility and conformational freedom in small HDL particles.
The enhanced mobility of the C-termini of APOA1 in small HDLs allows the C-termini to ‘flip’ off a particle’s surface, activating ABCA1 thereby stimulating cholesterol removal from cells.
Because of small HDLs’ vital role in cholesterol efflux, quantification of HDL-P (the size and concentration of HDL subspecies) might be a better metric for gauging cardiovascular disease risk than HDL-cholesterol levels.
Therapeutic interventions that increase small HDL levels, with or without increasing HDL-cholesterol levels, may be cardioprotective.
Competing Interest Statement
K.E.B. serves on the Scientific Advisory Board of Esperion Therapeutics.
Funding Statement
This work was supported by awards from the NIH: T32HL007828, R01HL149685, R35HL150754, P01HL151328, P01HL128203, P30DK017047, R01HL153118, R01HL155601, R01HL144558, and R01HL149685; the American Heart Association (15POST22700033); and the Intramural Program of the National Heart Lung and Blood Institute of the NIH. Anton 2 time was provided by the Pittsburgh Supercomputing Center (NIH R01GM116961).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committees/IRBs of Milano Area C, Italy (approval number 446-092014), New York University (approval number I14-01537) and the University of Washington (approval number STUDY00012123), gave ethical approval for this work. Ethics Committees in Italy are set up in structures identified by regions rather than by institutions.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Abbreviations and acronyms: ABCA1, ATP-binding cassette transporter A1; APOA1, apolipoprotein A1; APOB, apolipoprotein B; BHK, baby hamster kidney; calibrated IMA, calibrated ion mobility analysis; CEC, cholesterol efflux capacity; CVD, cardiovascular disease; EDC, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride; HDL-C, high-density lipoprotein cholesterol; HDL-P, HDL particle concentration determined by calibrated IMA; LCAT, lecithin–cholesterol acyltransferase; LDL-C, low-density lipoprotein cholesterol; L-HDL, large HDL; M-HDL, medium HDL; MS, mass spectrometry; r-HDL, reconstituted HDL; S-HDL, small HDL; XS-HDL, extra small HDL; MD, molecular dynamics.
Data availability
The authors confirm that the data supporting the findings of this study are available within the article and/or its supplementary materials.
